CEP-11981
As of the edition of 20 October 2026, CEP-11981 is a small molecule: stopped in 2022; acts on FLT1, FLT4 and KDR and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2022
- Kind
- Small molecule
- Registered trials
- 3, 1 stopped early
- Disease areas
- Cancer; Digestive system; Hormones; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 2 | 0 | 1 | 1 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Teva | Lead sponsor of trials | 2007 to now |